GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review - PubMed
6 hours ago
- #GLP-1 agonists
- #neuroprotection
- #systematic review
- GLP-1 receptor agonists show neuroprotective effects in stroke and Parkinson's disease models.
- In stroke models, GLP-1 agonists reduce infarct volume and improve neurological deficit scores.
- In Parkinson's disease models, they improve motor functions, preserve dopaminergic neurons, and decrease α-synuclein aggregation.
- GLP-1 agonists reduce neuroinflammatory, oxidative, and apoptotic markers.
- Treatment duration varied from 24 hours to 20 weeks, with moderate overall risk of bias in studies.
- Standardized studies and clinical trials are needed for translational potential.